BioStock

Prenumeration

Saniona comments on their new chapter in epilepsy treatment

2025-09-09 09:57:00

Saniona has selected SAN2668 as its first-in-class clinical candidate for epilepsy, following strong preclinical results that demonstrated robust efficacy and improved tolerability when benchmarked against existing treatments. Earlier this year, the company also secured a global licensing deal with Jazz Pharmaceuticals worth more than 1 billion USD, strengthening its ability to advance internal programs. We contacted Pierandrea Muglia, CMO of Saniona, for a comment on SAN2668.

Read the full interview at biostock.se:

Saniona comments on new chapter in epilepsy treatment

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden